Form 4: Neurocrine Biosciences CFO Matt Abernethy Executes Option and Sells Shares Under 10b5-1 Plan

Neurocrine Biosciences' Chief Financial Officer, Matt Abernethy, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On July 16, 2024, Matt Abernethy, the Chief Financial Officer of Neurocrine Biosciences Inc., exercised non-qualified stock options to acquire 900 shares of common stock at a price of $73.60 per share.
• Simultaneously, Abernethy sold 900 shares of common stock at a weighted average price of $150.0411 per share, with individual sales prices ranging from $150.00 to $150.18.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on February 13, 2024.
• Following these transactions, Abernethy directly owns 31,528 shares of Neurocrine Biosciences common stock and holds options for 14,100 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by a company executive under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is a standard practice in the pharmaceutical industry and is required by the SEC.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, including pharmaceutical firms like Neurocrine Biosciences.
• Companies like Amgen, Biogen, and Gilead Sciences also regularly file Form 4 documents when their executives trade company stock.
• The use of 10b5-1 trading plans is a common strategy among executives to avoid accusations of insider trading, aligning with industry best practices.

Stakeholder Impact

• Shareholders are informed about the CFO's stock transactions, providing transparency.
• The transactions may have a minor impact on stock price due to the sale of shares, but the effect is likely limited given the pre-planned nature of the trades.

Key Dates